EXELIXIS INC (NASDAQ:EXEL) – A High-Growth Momentum Stock with Strong Technical Setup

EXELIXIS INC (NASDAQ:EXEL) stands out as a high-growth momentum candidate with a solid technical setup. The company, focused on oncology treatments, has demonstrated strong earnings and revenue growth while also presenting a favorable chart pattern for potential breakout traders.

Growth Momentum Highlights

• Earnings Growth: EXEL has delivered impressive year-over-year EPS growth of 205.6% (TTM), with recent quarterly EPS growth at 175%.
• Revenue Growth: Sales growth over the past year stands at 24.5%, with the most recent quarter showing a 30.6% increase.
• Profit Margins Expanding: The company’s profit margin improved to 28.7% in the latest quarter, up from 24.7% in the prior quarter.
• Positive Earnings Surprises: EXEL has beaten EPS estimates in all of the last four quarters, with an average surprise of 55.5%.
• Analyst Revisions Upward: EPS estimates for the next year have been revised upward by 12.9% over the past three months.

Technical Strength & Setup

• Technical Rating (10/10): EXEL scores a perfect technical rating, reflecting strong upward momentum across short and long-term trends.
• Setup Quality (8/10): The stock is consolidating within a defined range, offering a potential breakout opportunity. Key resistance sits near $46.16, while support is found around $43.37.
• Relative Strength: EXEL outperforms 92% of all stocks in the market and 89% of biotechnology peers.
• Trend Confirmation: Both short-term and long-term trends are positive, with the stock trading above key moving averages (20, 50, 100, and 200-day SMAs).

For a deeper technical breakdown, review the full technical report on EXEL.

Our High Growth Momentum Breakout Setups Screen lists more stocks with strong growth and technical setups, updated daily.

Disclaimer

This is not investment advice. The observations here are based on current data, but investors should conduct their own research before making decisions.